Annovis Bio Inc.
| AMEX: ANVS | Healthcare / Biotechnology / USA |
| 10.68 | +0.3800 | +3.69% | Vol 339.36K | 1Y Perf -13.15% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 10.40 | ASK | 11.32 | ||
| Open | 10.62 | Previous Close | 10.30 | ||
| Pre-Market | - | After-Market | 10.82 | ||
| - - | 0.14 1.31% |
| Target Price | 46.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 330.71 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 28.48 | Earnings Rating | — | |
| Market Cap | 109.60M | Earnings Date | 14th Nov 2023 | |
| Alpha | 0.04 | Standard Deviation | 0.37 | |
| Beta | 1.42 |
Today's Price Range 10.4811.22 | 52W Range 5.4223.89 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 23.95% | ||
| 1 Month | 63.75% | ||
| 3 Months | -10.28% | ||
| 6 Months | -25.52% | ||
| 1 Year | -13.15% | ||
| 3 Years | 73.98% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -72.46 | |||
ROE last 12 Months | -81.15 | |||
ROA (5Y Avg) | -17.00 | |||
ROA last 12 Months | -77.27 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -73.90 | |||
Return on invested Capital Q | -23.55 | |||
Return on invested Capital Y | -55.73 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.80 | ||||
| 3.60 | ||||
| - | ||||
| - | ||||
| -7.90 | ||||
| -1.90 | ||||
| 3.60 | ||||
| 3.67 | ||||
| 75.78M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.70 | ||||
| 12.90 | ||||
| - | ||||
| - | ||||
| -237.80 | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -1.10 | -1.63 | -48.18 |
| Q02 2023 | -1.14 | -1.07 | 6.14 |
| Q01 2023 | -0.85 | -1.19 | -40.00 |
| Q04 2022 | - | -0.38 | - |
| Q03 2022 | -1.17 | -0.93 | 20.51 |
| Q02 2022 | - | -1.07 | - |
| Q01 2022 | - | -0.72 | - |
| Q03 2021 | - | -0.35 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -1.10 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 339.36K |
| Shares Outstanding | 10.26K |
| Shares Float | 6.33M |
| Trades Count | 3.48K |
| Dollar Volume | 3.66M |
| Avg. Volume | 242.60K |
| Avg. Weekly Volume | 399.16K |
| Avg. Monthly Volume | 215.77K |
| Avg. Quarterly Volume | 112.88K |
Annovis Bio Inc. (AMEX: ANVS) stock closed at 10.3 per share at the end of the most recent trading day (a 4.57% change compared to the prior day closing price) with a volume of 475.75K shares and market capitalization of 109.60M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2 people. Annovis Bio Inc. CEO is Maria Maccecchini.
The one-year performance of Annovis Bio Inc. stock is -13.15%, while year-to-date (YTD) performance is -23.31%. ANVS stock has a five-year performance of %. Its 52-week range is between 5.42 and 23.8881, which gives ANVS stock a 52-week price range ratio of 28.48%
Annovis Bio Inc. currently has a PE ratio of -3.80, a price-to-book (PB) ratio of 3.60, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -77.27%, a ROC of -73.90% and a ROE of -81.15%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Annovis Bio Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.10 for the next earnings report. Annovis Bio Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Annovis Bio Inc. is Strong Buy (1), with a target price of $46, which is +330.71% compared to the current price. The earnings rating for Annovis Bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Annovis Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Annovis Bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 36.43, ATR14 : 0.85, CCI20 : 199.68, Chaikin Money Flow : -0.14, MACD : 0.48, Money Flow Index : 90.19, ROC : 77.28, RSI : 76.38, STOCH (14,3) : 84.56, STOCH RSI : 1.00, UO : 49.43, Williams %R : -15.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Annovis Bio Inc. in the last 12-months were: Maria Maccecchini (Option Excercise at a value of $7 386), Maria-Luisa Maccecchini (Option Excercise at a value of $7 386)
Annovis Bio Inc.
Annovis Bio Inc is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
CEO: Maria Maccecchini
Telephone: +1 610 727-3913
Address: 1055 Westlakes Drive, Berwyn 19312, PA, US
Number of employees: 2
